Background and Aims: Management of branch-duct intraductal papillary mucinous neoplasms (BDIPMNs) remains challenging. We determined factors associated with malignancy in BD-IPMNs and longterm outcomes.
Introduction
Branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) are the most common variant of IPMNs, and are most often diagnosed incidentally. [1] [2] [3] Based on the International consensus guidelines (ICG) 2012 for the management of BD-IPMN, the indications for surgical resection rely on high-risk stigmata (HRS) and worrisome features (WF) on computed tomography (CT) and magnetic resonance imaging (MRI). 3 Endoscopic ultrasound-fine needle aspiration (EUS-FNA) has been increasingly utilized for the characterization of BD-IPMN lesions but its overall impact on the management of this disease remains unclear. Other imaging modalities like CT and MRI remain the first line of investigations in the majority of patients with an expanding body of literature backing this practice. [4] [5] [6] [7] [8] [9] [10] EUS has been suggested to be the most reliable tool for the characterization of IPMNs. 11 The ICG 2012 recommends possible EUS-FNA for evaluation of small BD-IPMNs without WF only in centers with expertise in EUS-FNA and cytological interpretation. 3 Recently, based on variable strength evidence, the American Gastroenterological Association Institute (AGA) released new guidelines on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. The guidelines suggest that pancreatic cysts with at least 2 high-risk features, such as size ≥ 3 cm, a dilated main pancreatic duct, or the presence of an associated solid component, should be examined with EUS-FNA; while patients with pancreatic cysts < 3 cm without a solid component or a dilated pancreatic duct should undergo MRI for surveillance. 12 Overall, all current guidelines derive many of their recommendations from lower level evidence from a limited number of studies. [13] [14] [15] Due to this and the lack of consistency across the current guidelines, the utility of EUS in the management of BD-IPMN remains controversial compared to other imaging modalities. While several studies have demonstrated variable associations between imaging features and malignancy in BD-IPMNs, the literature remains limited by small size series and the heterogeneity of the imaging modalities used including cross-sectional (CT/MRI) and/or endosonographic imaging studies.
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The primary objectives of our study were: 1) to evaluate the association between image-defined HRS and WF from ICG 2012 and malignant BD-IPMNs; and 2) to determine the diagnostic yield of preoperative EUS-FNA in identifying malignant BD-IPMNs. The secondary objectives were: 1) to measure recurrence rates of BD-IPMNs after resection during long term follow-up; and 2) to assess long term outcomes in BD-IPMNs patients undergoing imaging surveillance.
Methods

Study Population
This is a retrospective cohort study. cytopathology. The aspirated fluid was expressed onto 2 glass slides; one was air dried for rapid staining and on-site review and the other was alcohol fixed for future review. Performance of additional passes to obtain more fluid was left to the discretion of the endosonographer and the cytopathologist based on preliminary review of specimen adequacy. Following surgical resection, CT, MRI and/or EUS was performed periodically for surveillance. When patients were deemed poor surgical candidates, pancreatic cyst epithelial ablation with ethanol with or without paclitaxel injection was performed based on treating physician and patient's preferences as previously described. 17 For asymptomatic patients, imaging surveillance with EUS and CT/MRI was considered every 3-12 months as appropriate based on risks for malignancy. Since 2008, patients were rigorously followed within the Indiana University multidisciplinary pancreatic cyst program.
Cyst fluid analysis
Statistical Analysis
To compare patient and lesion characteristics between groups, the Student's t-test was performed for continuous variables and chi-square or Fisher's exact test for categorical variables. Continuous variables 6 were reported as mean±standard deviation (SD). Categorical variables were presented as number and percentages. Using surgical pathology as the reference standard, we calculated sensitivity/specificity/positive predictive value (PPV)/negative predictive value (NPV)/accuracy of predictive factors for identifying malignant behaviors that proved to be significantly different between benign and malignant group. In patients who achieved complete resection, we defined recurrence rates as a time-to-event outcome using the Kaplan Meier method and compared the survival of benign and malignant BD-IPMNs using a Log-Rank Test. A p value < 0.05 was considered statistically significant.
Statistical analyses were performed by using SPSS 16.0 for Windows software (SPSS, Chicago, Ill., USA).
Results
Patient characteristics
During the 13-year study period, we identified 364 patients with pure BD-IPMNs; 229 underwent imaging surveillance and 135 underwent surgical resection ( Figure 1 and Table 1 ). Compared to patients managed conservative, those surgically resected were more frequently found to be smokers and symptomatic at time of diagnosis. Mean time from diagnosis to surgery was 8.5±13.3 months. On CT/MRI/EUS studies, BD-IPMNs resected were larger size and less frequently multifocal. However, mean MPD size was not different between groups. Of 364 patients, HRS and WF according to the ICG 2012 were identified on CT/MRI in 2% and 34%, respectively; the remainder were non-WF patients (64%).
Indications for surgery based on the ICG 2012
Among the 135 resected BD-IPMNs, 117 were benign lesions (low-grade dysplasia in 81 and moderategrade dysplasia in 36) whereas 18 were malignant (high-grade dysplasia in 11, minimally invasive cancer in 5 and grossly invasive cancer in 2). The presence of HRS and WF on CT/MRI was similar between the benign and malignant groups, but the presence of MPD size 5-9 mm was more frequently associated with 7 malignancy (Table 2 ). Compared to benign BD-IPMNs, EUS-FNA features suspicious for malignancy were more frequently detected in malignant lesions, including definite mural nodules, MPD features suspicious for involvement, and suspicious/positive cytology for malignancy.
EUS features and cyst fluid analysis
Of 135 BD-IPMN patients managed surgically, EUS-FNA was performed in 105 (78%); 91 (78%) in benign and 14 (78%) in malignant lesions (Table 3 ). Compared to the benign group, patients with malignant lesions had greater mean MPD size, more frequent detection of mural nodules, and larger mean mural nodules size. Nevertheless, cyst diameter, increased cyst size over time prior to resection, multifocality, cyst location, cyst morphology (the presence of thickened wall, solid component, septations,
calcifications, and internal debris), and associated benign appearing lymphadenopathy were similar between groups. On cyst fluid analysis, median CEA and amylase, elevated DNA quantity, poor DNA quality, presence of KRAS point mutation, and LOH were not different between groups.
Diagnostic yields of preoperative EUS-FNA for identifying malignant BD-IPMNs
Given the association between malignancy and the presence of MPD size of 5-9 mm on CT/MRI as well as other EUS features, performance characteristics were calculated for these variables. Using surgical pathology as the reference standard, the sensitivity, specificity, PPV, NPV and accuracy of MPD dilation (5-9 mm) on CT/MRI for identifying malignancy and EUS features suspicious for malignancy were calculated (Table 4 ). Mural nodules identified by EUS were missed by CT/MRI in 4 (4%; size 5 mm) and 4 (28%; size 6-8 mm) in benign and malignant group, respectively.
Long term outcomes of patients managed surgically
Of 364 patients with BD-IPMNs, all 6 patients with HRS underwent surgery. Among 135 patients undergoing surgical resection, mean time from diagnosis to surgery and choice of operation were similar in the benign and malignant groups (Table 5 ). Mean length of stay, 30-day postoperative morbidity and 30-day mortality did not differ between groups. Death related to surgery occurred in 7 patients. Based on surgical pathology, complete resection was achieved in 95% and 100% of the benign and malignant groups, respectively. In benign BD-IPMNs with incomplete resection (n=6), all had low-grade dysplasia at the surgical margin and continued to be surveyed by imaging with stable lesion size during follow-up. Following surgery, 15 patients with benign lesions were lost to follow up. Mean duration of follow-up was not different between the benign and malignant groups. During a median follow-up period of 48 months (range: 6-160), no patient died from pancreatic cancer whereas 10 died from unrelated causes.
Long term outcomes of patients managed conservatively
Of 34 patients with WF undergoing imaging surveillance, stable cyst size, increased cyst size (benign cytology/molecular behavior), cyst ablation with and without response were identified in 27 (79%), 3 (9%), 1 (3%) and 1 (3%), respectively. Two patients with WF were lost to follow up after their first surveillance.
Of 185 non-WF patients undergoing imaging surveillance following benign or inconclusive cytology on EUS-FNA, stable cyst size, increased cyst size (benign cytology/molecular analysis), cyst ablation with and without response were observed in 166 (90%), 14 (8%), 3 (2%), and 1 (1%), respectively. One had distinct pancreatic adenocarcinoma with liver metastasis detected by EUS after 22 months of follow up; however;
MRI did not show any new lesions at 3 and 18 months earlier.
No patient was lost to follow in this group.
Of 10 patients undergoing EUS without FNA, 4 had stable cyst size on imaging surveillance and 6 were lost to follow up.
Of 6 patients undergoing cyst ablation, 4/6 had good response with cyst involution and symptom resolution; however, 2/6 had mild pancreatitis following the procedure. No patient undergoing cyst ablation developed cancer during follow-up.
Tumor recurrence rates
Analysis limited to patients with complete resection demonstrated recurrence to be more frequently observed in malignant BD-IPMNs (Table 5 ). Time to recurrence ranged from 4 to 39 months and from 4 to 90 months for benign and malignant group, respectively. Recurrent tumors were found at the resection margin in the pancreatic body in 2 patients; one identified in the benign group and the other in malignant group. All patients with recurrence had benign cytology at surveillance EUS-FNA and no patient underwent a second surgery. Using the Kaplan Meier method, patients with malignant BD-IPMNs had higher risk of recurrence during mean follow-up period of 131 months (p=0.01); recurrent tumors occurred as early as 34 months and as late as 94 months after the primary tumor was resected ( Figure 2 ).
Discussion
-Although several studies demonstrated the association between imaging features and malignant BD-IPMNs, these data were limited by small size series, the heterogeneity of the imaging modalities, the lack of long term follow-up particularly in patients undergoing imaging surveillance, and limited assessment of tumor behavior with EUS-FNA. 4-10, 18, 19 In a previous study from our group, the type and number of ICG WFs and HRS carried unequal weight and were not cumulative in the prediction of risk of malignancy in IPMN. 20 Although the cohort of patients followed in that study overlaps with the current one, the present study included additional 194 patients with BD-IPMN who underwent imaging surveillance. Moreover, the current study identified a pure cohort of patients with branched duct disease, the management of which represents a challenge given the prevalence of SB-IPMN and the lower risk of malignancy compared to main duct disease.
In the present study, we determined the association between malignant BD-IPMNs and HRS/WF on CT/MRI based on the ICG 2012 and specifically evaluated EUS characteristics of malignant BD-IPMNs.
Further, we present extended and rigorous follow up of patients within our multidisciplinary pancreatic cyst program. Among HRS and WF on CT/MRI, MPD size 5-9 mm was associated with malignant lesions, while EUS features were strongly associated with malignancy, including definite mural nodules, MPD features suspicious for involvement, and suspicious/malignant cytology. A possible explanation may be the limitation of CT/MRI in identifying features associated with malignancy in BD-IPMNs, particularly mural nodules. 21 Interestingly, we observed that 28% of mural nodules detected by EUS were missed by CT/MRI in the malignant group; with cyst size ranging between 2.1-3.5 cm. Among the malignant mural nodules missed by CT/MRI (n=4), 2 did not have any WF. In addition to the presence of mural nodules that were associated with malignant lesions, our study confirms the association of mean size of the mural nodule on EUS with malignancy (1.7 mm vs. 3.7 mm, p=0.02). While previous series demonstrated nodule size >7-10 mm on EUS being strongly associated with malignancy, 8, 11, 15, 22 we detected significantly smaller mural nodules in malignant BD-IPMNs.
Based on the new AGA guidelines, 8 patients were low risk individuals (AGA negative) based on CT/MRI (cysts < 3 cm without a solid component or a dilated pancreatic duct) but EUS identified HRS/WF (EUS positive) and led to resection. Of these 8 "AGA negative/EUS positive" patients, 2 were found to have mural nodules on EUS missed by MRI and with invasive malignancy proven on surgical pathology; whereas 6 had suspicious cytology for malignancy with benign histopathology at resection. While the ICG 2012 and recent AGA guidelines recommend a more conservative approach in patients without WF with cyst size 2-3 cm, our observations showed 2/38 (5.3%) patients in this group who underwent surgery due to mural nodules (found only on EUS); with minimally invasive cancer found at surgery. Although both ICG 2012
and AGA guidelines regard a cyst ≥ 3 cm as one of WF, we reported malignancy in smaller lesions (mean cyst size 2.9 cm vs. 2.2 cm in the benign vs. malignant group, respectively). Our findings suggest that the evaluation of BD-IPMNs with EUS is likely to influence on management options in a significant number of patients by detecting mural nodules otherwise missed on imaging or malignant cytology in lesions under 3 cm in size.
One of our main goals was to evaluate the performance characteristics of EUS for identifying malignant lesions. Mural nodules, MPD features suspicious for involvement and cytology suspicious/positive for malignancy were associated with malignant BD-IPMNs with high specificity (94%, 90% and 91%) and accuracy (86%, 83% and 82%), but low sensitivity (33%, 42% and 33%). Recently, a meta-analysis (4 studies, n=96) on the diagnostic yield of EUS-FNA-based cytology to distinguish malignant from benign
IPMNs showed a pooled sensitivity and specificity of 64.8% and 90.6%, respectively. However, data on BD-IPMNs specifically were not available in three studies included in the meta-analysis. In a limited number of cases in our study, molecular analysis did not add value to negative or inadequate cytology for identifying malignant behavior in patients with BD-IPMNs, which is consistent with our previous study. 23 Additionally, one recent meta-analysis (41 studies) reported the risk of malignancy associated with individual cyst features in IPMN to include cyst size > 3 cm, presence of a mural nodule, dilatation of the MPD and main vs. branch duct IPMN. 24 The other meta-analysis (23 studies) of imaging features to distinguish malignant and benign BD-IPMNs demonstrated strong association between mural nodules and malignancy, warranting surgical resection whereas cyst size ≥ 3 cm, MPD dilatation (5-9 mm), or thick septum/wall should be managed with careful observation and/or further evaluation. 5 However, more than 50% of studies included in both meta-analyses used variable imaging modalities, including CT, MRI, or EUS to assess the lesion characteristics, resulting in significant heterogeneity of the imaging modalities.
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Consistent with previous series, 9 we report 8% recurrence rate of BD-IPMN in the pancreatic remnant following surgical resection. Our data showed higher risk of benign-lesion recurrence in malignant BDIPMNs compared to benign ones during mean follow-up period of 131 months (17% vs. 7 %, p=0.03). Using the Kaplan Meier method, recurrence was documented in malignant lesions up to 8 years after resection, suggesting the need for long-term surveillance. Our observations demonstrated benign behavior in all patients with recurrent cystic lesions during surveillance, with no main duct involvement developing after a pure BD-IPMN has been resected.
Although the AGA guidelines suggest that patients with increasing lesion size should undergo EUS-FNA, we found that no patients in this group to have developed malignancy in the lesion. Similar to a previous study 9 limited to patients with complete resection, we observed no patients with IPMN-derived pancreatic adenocarcinoma during a median follow-up of 48 months. Several retrospective series reported distinct pancreatic adenocarcinoma in a different segment of the pancreas away from index IPMN lesion in up to 13 11% of patients during follow-up. [25] [26] [27] [28] [29] [30] [31] We observed 1 patient without WF with cyst size increasing by 50% during surveillance (with benign EUS-FNA cytology) who presented with pancreatic adenocarcinoma in a different part of the pancreas with liver metastasis after 22 months. These results highlight the "fielddefect concept" and the need for continued imaging surveillance in BD-IPMN. This concept could have future implications on the intensity of surveillance using imaging and tumor markers in some patients and might indeed call continued for long term care of these patients rather than termination of surveillance after periods of cyst stability as recently endorsed by the AGA guidelines. (Reference here AGA guidelines)
-There are some limitations to our study. Inherent to its retrospective design and the period of time it covers, there was variability in the management styles of some patients in the cohort, particularly surgical resection referrals. Despite having lost 3% and 11% of patients to follow up in the conservative and surgical resection groups respectively; we provided long term follow-up on most patients particularly those undergoing imaging surveillance.
We also described a unique group of patients with histologic diagnosis of pure BD-IPMNs without MPD involvement when compared to the cross-sectional and EUS imaging.
In conclusion, our study further endorses the practice of incorporating EUS in the management of most SB-IPMNs. Its ability to detect mural nodules missed by CT/MRI highlights the limitation of CT/MRI in predicting malignancy in some BD-IPMN lesions. The high specificity and accuracy of EUS features of malignancy we report herein strongly position EUS-FNA as the optimum tool for diagnosing malignant BDIPMNs, particularly in patients without WF and those with smaller cysts. (29) 0.04 *Lack of mobility, adherence to the cyst wall, presence of doppler flow, lack of echogenic stratification seen in mucous aggregates, and/or FNA of nodule itself confirming the presence of tumor tissue **Presence of any of the following criteria: thickened walls, intraductal mucin or mural nodules is suggestive of MPD involvement 
